ACLARION INC (ACON)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$2.35+2.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Broken: Primary pillar broken — Operating income improvement from -$2.99M in 2026-Q1: metric not reported.
Aclarion aims to grow revenue 26% next year to $135 million. It plans to improve operating income from -$2.99 million in 2026-Q1. The company is expanding clinical trials, which supports growth and cost control. A $2.5 million share buyback shows confidence in value.
Aclarion is loss-making with operating income worsening from -$1.74 million to -$2.99 million. EPS is expected negative at -$4.51 for 2026 and -$5.47 for 2027. Revenue growth may slow as the market prices in 26% growth but implied longer-term growth is negative.
The market expects about 26% revenue growth next year and values the stock near $9.27. Our view aligns with consensus revenue growth but is cautious on operating income and profitability, which remain weak.
Breaks if: Buyback program is cancelled or unused by end of 2026
Breaks if: No new clinical trial expansions announced in next 4 quarters
Breaks if: Operating loss worsens beyond -$3.5M in any quarter
Aclarion aims to improve its operating income, which has been negative in recent quarters.
Stated in 4 of last 4 quarters. Operating income has been negative, worsening from -$1,736,508 in 2025-Q2 to -$2,986,941 in 2026-Q1. The trajectory shows limited progress in improving operating income, indicating a need for strategic cost management.
“Operating income was -$2,986,941 in 2026-Q1.”
“Operating income was -$1,992,994 in 2025-Q4.”
“Operating income was -$1,830,964 in 2025-Q3.”
“Operating income was -$1,736,508 in 2025-Q2.”
Breaks if: YoY revenue growth falls below 20% in FY26
Aclarion has entered into a Material Definitive Agreement as part of its M&A strategy.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
ACON represents a speculative growth investment with a focus on potential recovery. The current thesis state indicates a watchful approach due to recent underperformance and high risk factors.
The market seems to have priced in a low level of fragility, with expectations indicating a significant gap. ACON's valuation is at a premium compared to peers, suggesting that investors may be anticipating a turnaround despite current losses.
Fundamentals are likely to remain weak in the near term, as the company continues to report negative operating income. Management has expressed intentions to improve this area, but progress has been limited.
The thesis hinges on external factors such as the performance of sector bellwethers and overall economic conditions. A favorable or unfavorable shift in these areas could significantly impact ACON's trajectory.
In the next 1 to 3 years, ACON's outlook will depend on its ability to improve financial performance amid high risk and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.